|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||0.5375 - 0.5825|
|52-week range||0.4630 - 2.1200|
|Beta (5Y monthly)||1.20|
|PE ratio (TTM)||N/A|
|Earnings date||17 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
OXNARD, Calif., Jun 15, 2021--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer Jonathan Berlent will participate in a virtual presentation at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17.
CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company, (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.
Nicole Kidman and Sera Labs Inc., a CURE Pharmaceutical Company, launch clean, plant-based beauty line Seratopical Revolution, and new ad campaign.